48 related articles for article (PubMed ID: 26086760)
1. Advancing gene targeting for primary immune deficiencies: Adenine base editing of the human IL2RG locus for correction of SCID-X1.
McIvor RS; Eaton EJ; Webber BR; Moriarity BS
Mol Ther; 2024 Jun; 32(6):1606-1608. PubMed ID: 38781958
[No Abstract] [Full Text] [Related]
2. GMP-Grade Manufacturing and Quality Control of a Non-Virally Engineered Advanced Therapy Medicinal Product for Personalized Treatment of Age-Related Macular Degeneration.
Kropp M; Harmening N; Bascuas T; Johnen S; De Clerck E; Fernández V; Ronchetti M; Cadossi R; Zanini C; Scherman D; Ivics Z; Marie C; Izsvák Z; Thumann G
Biomedicines; 2022 Nov; 10(11):. PubMed ID: 36359296
[TBL] [Abstract][Full Text] [Related]
3. Towards safe therapy for immunodeficiency.
Tsai SQ
Nat Biomed Eng; 2017 Dec; 1(12):937-938. PubMed ID: 31015711
[No Abstract] [Full Text] [Related]
4. Nuclease-free Adeno-Associated Virus-Mediated Il2rg Gene Editing in X-SCID Mice.
Hiramoto T; Li LB; Funk SE; Hirata RK; Russell DW
Mol Ther; 2018 May; 26(5):1255-1265. PubMed ID: 29606506
[TBL] [Abstract][Full Text] [Related]
5. Lymphoid regeneration from gene-corrected SCID-X1 subject-derived iPSCs.
Menon T; Firth AL; Scripture-Adams DD; Galic Z; Qualls SJ; Gilmore WB; Ke E; Singer O; Anderson LS; Bornzin AR; Alexander IE; Zack JA; Verma IM
Cell Stem Cell; 2015 Apr; 16(4):367-72. PubMed ID: 25772073
[TBL] [Abstract][Full Text] [Related]
6. Gene therapy for SCID-X1: focus on clinical data.
Baum C
Mol Ther; 2011 Dec; 19(12):2103-4. PubMed ID: 22134740
[No Abstract] [Full Text] [Related]
7. T-cell-replete haploidentical bone marrow transplantation for X-linked severe combined immunodeficiency.
Ariffin H; Chew KS; Jawin V; Thavagnanam S
Singapore Med J; 2020 May; 61(5):284-285. PubMed ID: 30128577
[No Abstract] [Full Text] [Related]
8. Toward Clinical Translation of New Gene Targeting Technologies for Correcting Inherited Mutations and Empowering Adoptive Immunotherapy of Cancer (SUPERSIST).
Hum Gene Ther Clin Dev; 2015 Jun; 26(2):95-7. PubMed ID: 26086760
[No Abstract] [Full Text] [Related]
9. Optimizing outcomes of hematopoietic stem cell transplantation for severe combined immunodeficiency.
Cuvelier GD; Schultz KR; Davis J; Hirschfeld AF; Junker AK; Tan R; Turvey SE
Clin Immunol; 2009 May; 131(2):179-88. PubMed ID: 19217351
[TBL] [Abstract][Full Text] [Related]
10. [T-cell therapy in oncology. Therapeutic vaccination, allogeneic blood stem cell transplantation and adoptive T-cell transfer].
Kuball J; Derigs HG; Wölfel T
Dtsch Med Wochenschr; 2002 Apr; 127(14):755-62. PubMed ID: 11935475
[No Abstract] [Full Text] [Related]
11. [Gene therapy of SCID-X1].
Baum C; Schambach A; Modlich U; Thrasher A
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2007 Dec; 50(12):1507-17. PubMed ID: 18046520
[TBL] [Abstract][Full Text] [Related]
12. Adoptive immunotherapy with genetically modified lymphocytes in allogeneic stem cell transplantation.
Cieri N; Mastaglio S; Oliveira G; Casucci M; Bondanza A; Bonini C
Immunol Rev; 2014 Jan; 257(1):165-80. PubMed ID: 24329796
[TBL] [Abstract][Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
